HIV/AIDS Update - Prezista (darunavir) tablet and oral suspension: pediatric dosing

On February 1, 2013, FDA approved revisions to the Prezista
(darunavir) tablet and oral suspension label to include once daily
dosing in treatment-naïve subjects 3 to less than 18 years of
age and once daily dosing in treatment-experienced...

Source: Drugs.com - Pharma News - February 4, 2013 Category: Pharmaceuticals Source Type: news